ARNA - $3.71 (0.05) Arena Pharmaceuticals, Inc. - Latest Stock Market News and Blogs

Arena Seeking a Full BLOOM

Friday December 19, 2008 — Zacks.com: Analyst Blog

Arena Pharmaceuticals, Inc.'s (ARNA) leading pipeline candidate, lorcaserin for obesity, continues is its phase III program. Although we remain somewhat skeptical of lorcaserin's potential, Arena's stock is looking attractive on a long-term basis given the likelihood that Arena will event...

Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals

Tuesday December 16, 2008 — Arena Pharmaceuticals, Inc.

SAN DIEGO, Dec. 15 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. announced today that Ortho-McNeil-Janssen Pharmaceuticals, Inc. (Ortho-McNeil) initiated under their partnership a first-in-human Phase 1 clinical trial of APD597, a novel oral drug candidate discovered by Arena that target...

Arena Pharmaceuticals Announces Preliminary Results of Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia

Wednesday December 10, 2008 — Arena Pharmaceuticals, Inc.

SAN DIEGO, Dec. 9 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. today announced preliminary data from a Phase 2b clinical trial of APD125 measuring subjective endpoints in patients with primary insomnia. The initial data analysis indicates that APD125 did not meet the trial's primary or ...

Arena Pharmaceuticals Announces Lorcaserin Phase 2b Clinical Trial Results Published in Obesity

Monday December 8, 2008 — Arena Pharmaceuticals, Inc.

SAN DIEGO, Dec. 8 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. announced today publication of the Phase 2b clinical trial results of lorcaserin, its novel drug candidate for the treatment of obesity, in the December 4, 2008 issue of Obesity, the official peer reviewed journal of The Obe...

Arena Pharmaceuticals to Host Research & Development Day on December 15, 2008

Monday December 8, 2008 — Arena Pharmaceuticals, Inc.

SAN DIEGO, Dec. 8 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. announced today that it will host a Research and Development Day on Monday, December 15, 2008, beginning at approximately 12:00 p.m. Eastern Time (9:00 a.m. Pacific Time). Speakers, including Jack Lief, President and Chief E...

Arena Pharmaceuticals to Present at the Piper Jaffray 20th Annual Health Care Conference

Tuesday November 25, 2008 — Arena Pharmaceuticals, Inc.

SAN DIEGO, Nov. 25 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. announced today that the company is scheduled to present at the Piper Jaffray 20th Annual Health Care Conference on December 3, 2008 at 2:30 p.m. Eastern Time (11:30 a.m. Pacific Time) at the New York Palace Hotel in New Yo...

Arena: No Near-Term Relief

Friday October 31, 2008 — Zacks.com: Analyst Blog

Arena Pharmaceuticals (ARNA) reported financial results for the third quarter 2008. Although results were largely in-line with expectations, investors are starting to take notice of Arena's cash position. Despite the $212.1 million still on the books at the end of September 2008, manageme...

Arena Pharmaceuticals Announces Third Quarter 2008 Financial Results

Friday October 31, 2008 — Arena Pharmaceuticals, Inc.

SAN DIEGO, Oct. 30 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. today reported financial results for the third quarter ended September 30, 2008.Arena reported a net loss allocable to common stockholders in the third quarter of 2008 of $56.2 million, or $0.76 per share, and a net loss al...

Arena Pharmaceuticals to Present at the Oppenheimer 19th Annual Healthcare Conference

Wednesday October 29, 2008 — Arena Pharmaceuticals, Inc.

SAN DIEGO, Oct. 29 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. announced today that the company is scheduled to present at the Oppenheimer 19th Annual Healthcare Conference on November 4, 2008 at 8:40 a.m. Eastern Time (5:40 a.m. Pacific Time) at the Waldorf=Astoria Hotel in New York C...

Arena Pharmaceuticals to Report Third Quarter 2008 Financial Results and to Host Conference Call and Webcast on Thursday, October 30, 2008

Thursday October 23, 2008 — Arena Pharmaceuticals, Inc.

SAN DIEGO, Oct. 23 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. today announced it will report third quarter 2008 financial results after the NASDAQ Global Market closes on Thursday, October 30, 2008. That same afternoon, Jack Lief, Arena's President and Chief Executive Officer, and Rob...

Arena Pharmaceuticals to Present at the BIOCOM Investor Conference

Wednesday October 22, 2008 — Arena Pharmaceuticals, Inc.

SAN DIEGO, Oct. 22 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. announced today that the company is scheduled to present at the BIOCOM Investor Conference on October 28, 2008 at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) at the Hyatt Regency Hotel in La Jolla, California. Jack Lief...

Arena Pharmaceuticals to Present at the Natixis Bleichroeder Second Annual Hidden Gems Conference

Tuesday October 7, 2008 — Arena Pharmaceuticals, Inc.

SAN DIEGO, Oct. 7 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. announced today that the company is scheduled to present at the Natixis Bleichroeder Second Annual Hidden Gems Conference on October 13, 2008 at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time) at the Waldorf=Astoria Hotel in...

Arena Pharmaceuticals to Present at the UBS Global Life Sciences Conference

Wednesday September 17, 2008 — Arena Pharmaceuticals, Inc.

SAN DIEGO, Sept. 17 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. announced today that the company is scheduled to present at the UBS Global Life Sciences Conference on September 23, 2008 at 11:00 a.m. Eastern Time (8:00 a.m. Pacific Time) at the Grand Hyatt Hotel in New York City. Domin...

Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference

Thursday August 28, 2008 — Arena Pharmaceuticals, Inc.

SAN DIEGO, Aug. 28 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. announced today that the company is scheduled to present at the NewsMakers in the Biotech Industry Conference on September 4, 2008 at 11:00 a.m. Eastern Time (8:00 a.m. Pacific Time) at the Millennium Broadway Hotel in New ...

Arena Pharma Needs More Data

Thursday August 7, 2008 — Zacks.com: Analyst Blog

Arena Pharmaceuticals Inc.'s (ARNA) leading pipeline candidate, lorcaserin for obesity, continues is its phase III program. Although we remain somewhat skeptical of lorcaserin's blockbuster potential, the stock is beginning to look attractive on a long-term basis given the likelihood that...

Arena Pharmaceuticals Announces Second Quarter 2008 Financial Results and Recent and Second Quarter Highlights

Wednesday August 6, 2008 — Arena Pharmaceuticals, Inc.

SAN DIEGO, Aug. 5 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. today reported financial results for the second quarter ended June 30, 2008.Total revenues in the second quarter of 2008 were $2.6 million, compared to $4.8 million in the second quarter of 2007, and included $2.0 million in...

Arena Pharmaceuticals to Report Second Quarter 2008 Financial Results and to Host Conference Call and Webcast on Tuesday, August 5, 2008

Wednesday July 30, 2008 — Arena Pharmaceuticals, Inc.

SAN DIEGO, July 29 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. today announced it will report second quarter 2008 financial results after the NASDAQ Global Market closes on Tuesday, August 5, 2008. That same afternoon, Jack Lief, Arena's President and Chief Executive Officer, and Rober...

Staying Neutral on Arena Pharma

Friday July 11, 2008 — Zacks.com: Analyst Blog

Arena Pharmaceuticals, Inc.'s (ARNA) leading pipeline candidate, lorcaserin for obesity, is in phase III trials. Although we remain somewhat skeptical of the drug's sales potential, the stock is beginning to look attractive on a long-term basis given its likelihood of signing a commercial...

Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis

Wednesday July 9, 2008 — Arena Pharmaceuticals, Inc.

SAN DIEGO, July 9 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. today announced positive results from a multiple-ascending dose Phase 1b clinical trial of APD791 to evaluate the compound's safety, pharmacokinetics and pharmacodynamics. APD791 is Arena's internally discovered oral drug ca...